Citrix Systems, Watson Pharmaceuticals: S&P Gainers
The stock hit a 52-week high Thursday of $75.95 following the announcement Wednesday that Watson Pharmaceuticals is acquiring Swiss generic drug maker Actavis for $5.6 billion.
Watson Pharmaceuticals' forward P/E is 11.58X; the average for pharmaceutical companies is 22.68X. For comparison, Perrigo(PRGO) has a higher forward P/E of 19.39X.
Seventeen of the 24 analysts who cover Watson Pharmaceuticals rated it buy; seven analysts gave the stock a hold rating.
TheStreet Ratings gives Watson Pharmaceuticals an A grade with a buy rating and $82.18 price target. The stock has risen 23.32% year to date.